Director/PDMR Shareholding
Updated : 09:13
28 August 2019
Intelligent Ultrasound Group plc
("Intelligent Ultrasound" or the "Company")
Director Dealings
Intelligent Ultrasound (AIM: MED), the intelligent ultrasound software and simulation company, announces that further to the Company's announcements on 8 August 2019 and 27 August 2019, certain Directors have, following Admission today, acquired a total of 500,000 Ordinary Shares in the Company ("Ordinary Shares") via the Placing, as detailed below:
Name | Title | Number of Placing Shares | Value of Placing Shares | Resultant | Percentage of enlarged share |
Stuart Gall | Chief Executive Officer | 200,000 | £20,000 | 828,236 | 0.38% |
Wilson Jennings | Finance Director | 100,000 | £10,000 | 394,118 | 0.18% |
Nicholas Sleep | Chief Technology Officer | 100,000 | £10,000 | 326,471 | 0.15% |
Ian Whittaker | Chief Operating Officer | 25,000 | £2,500 | 374,982 | 0.17% |
Nick Avis | Non-Executive Director | 25,000 | £2,500 | 225,000 | 0.10% |
Nazar Amso | Non-Executive Director | 50,000 | £5,000 | 1,134,000 | 0.52%
|
In addition to the above:
Professor Nazar Amso is the beneficial holder of 180,000 Ordinary Shares through The Amso Trust and Professor Nazar Amso's spouse holds 120,000 Ordinary Shares.
# The number of Ordinary Shares presented in this table as being held or subscribed for by Directors refers to the number of Ordinary Shares held or subscribed for by them either personally or through a nominee.
Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as defined in the circular sent to shareholders of the Company on 8 August 2019.
The Company makes the following disclosures in accordance with article 19(3) of the Market Abuse Regulation:
1 | Details of the person discharging managerial responsibilities / person closely associated | |||||
a)
| Name
| 1. Stuart Gall 2. Wilson Jennings 3. Nicholas Sleep 4. Ian Whittaker 5. Nick Avis 6. Nazar Amso | ||||
2 | Reason for the notification | |||||
a)
| Position/status
| 1. Chief Executive Officer 2. Finance Director 3. Chief Technology Officer 4. Chief Operating Officer 5. Non-Executive Director 6. Non-Executive Director
| ||||
b) | Initial notification /Amendment | Initial | ||||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Intelligent Ultrasound Group plc | ||||
b) | LEI | 213800K4ZVWL4ZYQAZ70 | ||||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a)
| Description of the financial instrument, type of instrument
Identification code | Ordinary Shares of 1 pence each
ISIN: GB00BN791Q39 | ||||
b) | Nature of the transaction | Purchase of Ordinary Shares | ||||
c)
| Price(s) and volume(s)
|
| ||||
d) | Aggregated information - Aggregated volume - Price |
N/A - single transaction | ||||
e) | Date of the transaction | 28 August 2019 | ||||
f) | Place of the transaction | London Stock Exchange, XLON |
Enquiries:
Intelligent Ultrasound Group plc | |
Stuart Gall, CEO | Tel: +44 (0)29 2075 6534 |
Cenkos Securities | Tel: +44 (0)20 7397 8900 |
Giles Balleny (Nominated Adviser) | |
Michael Johnson/Julian Morse (Corporate Broking) | |
Walbrook PR | Tel: +44 (0)20 7933 8780 |
Anna Dunphy/Paul McManus | Mob: +44 (0)7876 741 001/Mob: +44 (0)7980 541 893 |
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.